Wegovy liver benefits in MASH went beyond weight loss, Novo Nordisk analyses say
New analyses link Wegovy to liver improvements in MASH that weight loss alone does not explain, adding detail to an FDA approval that is still under accelerated review.
Novo Nordisk reported analyses dated Nov. 10, 2025 showing that Wegovy (semaglutide 2.4 mg) was associated with liver health-related benefits in adults with MASH who have liver scarring, and that those benefits were not solely based on weight loss [1]. The data came after the FDA granted Wegovy accelerated approval for MASH on Aug. 15, 2025 [1].
MASH stands for metabolic dysfunction-associated steatohepatitis; it was formerly called nonalcoholic steatohepatitis, or NASH [1]. Wegovy's approved MASH indication covers adults with noncirrhotic MASH and moderate to advanced liver fibrosis, described in the product label as consistent with stages F2 to F3 [1]. Fibrosis is scar tissue in the liver.
Wegovy's label states that the drug is thought to work in MASH through multiple pathways mediated by weight loss and other factors [1]. The November analyses point to liver effects that weight reduction alone does not explain [1]. Which pathways are involved, and how much of the liver benefit they account for, has not been disclosed, and no figures for the degree of improvement in liver tissue or scarring were reported with the analyses [1].
An approval still being verified
The MASH indication was granted under accelerated approval based on improvement of MASH and fibrosis [1]. Under that pathway, continued approval for the indication may depend on verification and description of clinical benefit in a confirmatory trial [1]. Results from that trial and the date they are expected have not been reported [1].
Wegovy is also approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain weight reduction long term in certain adults and in children aged 12 and older with obesity [1]. The drug was first approved by the FDA on June 4, 2021 [1].
The MASH dose studied in the analyses is 2.4 mg, given as a once-weekly subcutaneous injection [1]. The label carries a boxed warning for an increased risk of thyroid C-cell tumors, and warnings for acute pancreatitis, acute gallbladder disease, low blood sugar, acute kidney injury, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, increased heart rate, suicidal behavior and ideation, and pulmonary aspiration during general anesthesia or deep sedation [1]. Common side effects reported in at least 5 percent of adults or children aged 12 and older include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, abdominal bloating, belching, low blood sugar in patients with type 2 diabetes, gas, gastroenteritis, acid reflux and nasal congestion [1]. Wegovy is not recommended for use with another semaglutide product or any other GLP-1 receptor agonist [1].
Why it matters for patients
MASH with moderate to advanced scarring is a liver condition that can progress, and it often causes no obvious symptoms in its earlier stages. For adults who already take Wegovy for weight management or heart risk and who also have MASH with F2 to F3 fibrosis, the November analyses offer a second, liver-specific explanation for why the drug may help, separate from the number on the scale. That distinction could matter for patients whose weight loss is modest or slows over time.
At the same time, the evidence behind this indication is not final. Accelerated approval was based on improvement in liver tissue and scarring rather than on proven reductions in harder outcomes such as cirrhosis, liver failure or liver-related death, and the FDA has said continued approval may depend on a confirmatory trial [1]. No such outcomes data, and no timeline for them, has been disclosed [1]. The analyses also did not include patient counts, trial names or duration, so how broadly the findings apply across different patients is not known [1].
What happens next
Novo Nordisk has not reported when confirmatory trial results for the MASH indication will be available [1]. Wegovy remains approved for MASH in adults with noncirrhotic disease and F2 to F3 fibrosis in the meantime [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.